A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours
| Autor: | Priscilla B. Pujatti, Maria Tereza Colturato, Emiko Muramoto, C.P.G. Silva, R.M. Couto, J.S. Caldeira Filho, E.B. de Araújo, L.T. Nagamati, Jair Mengatti |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Biodistribution Peptide Lutetium Iodine Radioisotopes chemistry.chemical_compound Heterocyclic Compounds 1-Ring Mice Pharmacokinetics In vivo Internal medicine medicine Radioligand DOTA Animals Tissue Distribution Radionuclide Imaging Chelating Agents chemistry.chemical_classification Radioisotopes Radiation Chemistry In vitro Neuroendocrine Tumors Endocrinology Somatostatin Radiopharmaceuticals |
| Zdroj: | Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine. 67(2) |
| ISSN: | 1872-9800 |
| Popis: | This work analysed the influence of the chelating group and radioligand on somatostatin analogues in vivo and in vitro properties. The presence of DOTA in the radioiodinated peptide produced a labeled analogue with similar blood kinetics and biodistribution to (177)Lu-DOTATATE and with lower abdominal uptake than (131)I-TATE. In addition, (131)I-DOTATATE showed significative tumour uptake, despite not so persistent after 24h. (131)I-DOTATATE can represent a cost-effective alternative to lutetium labeled peptide for neuroendocrine tumours therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect